Interactive Features

Quiz

Nab-paclitaxel Plus Gemcitabine-Cisplatin by Primary Location of Biliary Tract Cancer

02/10/2023

Although it did not meet its primary end point of improved overall survival, the phase 3 SWOG 1815 trial suggested gemcitabine-cisplatin plus nab-paclitaxel may show benefit in which primary tumor location of biliary tract cancer?

Although it did not meet its...

02/10/2023

Oncology

Quiz

Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma

12/01/2022

How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...

How did the outcomes of patients...

12/01/2022

Oncology

Quiz

Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer

11/30/2022

What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?

What was the approximate...

11/30/2022

Oncology

Quiz

Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

11/02/2022

In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

In the phase 2 FIDES-01 study,...

11/02/2022

Oncology

Quiz

True or False: In the phase 2 FIDES-01 study, derazantinib was found to have a comparable toxicity profile to other FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib.

10/21/2022

In the phase 2 FIDES-01 study, was derazantinib found to have a comparable toxicity profile to other small molecule, FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib?

In the phase 2 FIDES-01 study,...

10/21/2022

Oncology

Quiz

Quiz: Durvalumab Added to Gemcitabine-Cisplatin for Biliary Tract Cancers

09/02/2022

In the TOPAZ-1 trial which determined whether the addition of durvalumab to gemcitabine-cisplatin chemotherapy conferred a survival benefit for patients with advanced or metastatic biliary tract cancers, which primary tumor location saw...

In the TOPAZ-1 trial which...

09/02/2022

Oncology

Test Your Knowledge

Quiz: What Test Can Be Used to Compare OS, DFS in ICC?

02/24/2022

Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?

Which test can be used to...

02/24/2022

Oncology

Test Your Knowledge

Quiz: What Test Can Be Used to Compare OS, DFS in ICC?

02/24/2022

Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?

Which test can be used to...

02/24/2022

Oncology

Quiz

Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?

02/14/2022

The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.

The FDA’s approval of...

02/14/2022

Oncology

Quiz

Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?

02/14/2022

The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.

The FDA’s approval of...

02/14/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology